Tizanidine
Product Images NDC 16590-221

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 16590-221). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tizanidine 2mg Label Image (Tizanidine 2mg Label)

Tizanidine 2 mg tablets, generic for Zanaflex, packaged by STAT Rx USA LLC. The label shows a bottle containing 90 tablets. The product is manufactured by Dr. Reddy's Laboratories in India. The NDC is 16590-220-90. The label includes dosage information and warnings about use and storage.*

FDA Label Image

Tizanidine 4mg Label Image (Tizanidine 4mg Label)

Tizanidine 4 mg tablet label by STAT Rx USA LLC, generic for Zanaflex, with a 30 count package. The label includes NDC 16590-221-30, dosage information, manufacturer details (Dr. Reddys Labs Ltd.), and warnings about drowsiness and alcohol use. The label also states RX only and to keep out of reach of children.*

FDA Label Image

Structure Image (Tizanidine Chem Struct)

Chemical structure of Tizanidine hydrochloride, showing its molecular configuration with characteristic rings and chlorine atom.*

FDA Label Image

Figure 1 Image (Fig1)

A line graph depicting improvement in Ashworth Score over time (hours post-dose) for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis measures improvement in the Ashworth Score, with data points plotted at 0, 1, 2, 3, and 6 hours post-dose, including error bars for each measurement.*

FDA Label Image

Figure 2 Image (Fig2)

A line plot showing improvement in Ashworth Score over time for tizanidine and placebo groups. The x-axis marks 'End of Titration (Study Week 3)', 'End of Maintenance (Study Week 7)', and 'Endpoint (Last Observation Carried Forward)', while the y-axis measures improvement ranging from -6 to 2. The tizanidine group (mean dose 28.8 mg) shows greater improvement with error bars, compared to the placebo group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.